Sienna Biopharmaceuticals, Inc. (OTCMKTS: SNNAQ) is a specialty pharmaceutical company dedicated to the development, commercialization and acquisition of prescription therapies for dermatologic conditions. The company focuses on inflammatory skin disorders, hair loss and aesthetic applications by leveraging both in-licensing partnerships and targeted in-house research to bring novel and established treatments to market.
In 2020, Sienna launched ZILXI® (minocycline) foam 1% in the United States following FDA approval for the topical treatment of inflammatory lesions of rosacea. Its clinical pipeline includes SB206, a topical hair regrowth candidate in development for androgenetic alopecia, as well as other formulations aimed at acne and additional chronic skin diseases. These programs are supported by collaborations with academic centers and industry partners to advance clinical development and regulatory filings.
Founded in 2014 and headquartered in Vancouver, Washington, Sienna Biopharmaceuticals operates primarily across the U.S. market, with strategic plans to expand internationally through licensing and distribution agreements. The company has built a commercial infrastructure—including regulatory, medical affairs and manufacturing capabilities—to support product launches and long-term growth in high-unmet-need dermatology segments.
Led by CEO John P. Jury, who brings over three decades of experience in dermatology product development and commercialization, Sienna’s leadership team combines expertise in regulatory affairs, medical science, and business development. This governance structure is designed to efficiently advance the company’s pipeline, optimize its marketed portfolio and address evolving needs of physicians, payers and patients.
AI Generated. May Contain Errors.
